You are here
Peptide motif analysis predicts lymphocytic choriomeningitis virus as trigger for multiple sclerosis
Molecular Immunology, Volume 67, Issue 2, Part B, October 2015, Pages 625–635
- Professor Comi emphasized how little was known about the pathophysiology of the progressive phases in relapsing remitting multiple sclerosis. It...
Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system (Review Article)Journal of Neuroimmunology, Volume 287, 15 October 2015, Pages 80–87
Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis
Lenka Novakova, Markus Axelsson, Clas Malmeström, Henrik Zetterberg, Ingemar Björkhem, Virginija Danylaité Karrenbauer, Jan Lycke
Journal of the Neurological Sciences, Volume 358, Issue 1-2, November 2015, Pages 201 - 206
Intracortical inhibition abnormality during the remission phase of multiple sclerosis is related to upper limb dexterity and lesions
Julia C. Nantes, Jidan Zhong, Scott A. Holmes, Benjamin Whatley, Sridar Narayanan, Yves Lapierre, Douglas L. Arnold, Lisa Koski
Clinical Neurophysiology, In Press, Corrected Proof, Available online 31 August 2015, Available online 31 August 2015
Presence of the HLADR13 allele among Mexican Mestizos suggests a protective factor against relapsing-remitting multiple sclerosis (RRMS)
José Flores, Julio Granados, E. Alonso, Yamel Rito, Esteban Ortega-Hernández, Lourdes Mena-Hernández, Teresa Corona
Clinical Neurology and Neurosurgery, Volume 138, November 2015, Pages 184–187
- Dr. de Luca explains in his talk that multiple sclerosis was unsurpassed in its variability and clinical outcomes. One of the greatest determinants of disease and disability was entry into the progressive phase.
- In her speech, the award winner Dr. Airas, said that it had been very difficult to find treatments for progressive multiple sclerosis. One reason was that the pathology changes as the disease progresses.
George E. Davis, Walter E. Lowell
Journal of Photochemistry and Photobiology B: Biology, October 2015, Pages 46 - 47
Peroxisome Proliferator Activated Receptor-γ agonists protect oligodendrocyte progenitors against Tumor Necrosis Factor-alpha-induced damage: Effects on mitochondrial functions and differentiationExperimental Neurology, Volume 271, September 2015, Pages 506-514
TNF-α and the mitochondrial toxin rotenone cause detrimental effects on mitochondrial functions and OL differentiation.
PPAR-γ agonists prevent the effects of TNF-α and rotenone.
The PPAR-γ agonists increase the expression of PGC-1α, UCP2, and cytochrome oxidase subunit COX1.
PPAR-γ agonists protect OL from TNF-α insult by inducing mitochondrial biogenesis and protecting from mitochondrial ROS.